文献速递肝病消化道肿瘤与早癌

RACK1的O-GlcNAc糖基化促进肝细胞癌发生

O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis.
PubMed 文献 · J Hepatol · 2018-02-15

该研究探讨RACK1的O-GlcNAc糖基化在癌基因翻译和肝细胞癌发生中的作用。研究发现核糖体RACK1在Ser122位点被O-GlcNAc高度修饰,增强其蛋白稳定性、核糖体结合及与PKCβII的相互作用,促进真核翻译起始因子4E磷酸化和强效癌基因翻译。基因敲除RACK1 Ser122位点O-GlcNAc糖基化可抑制肿瘤发生、血管生成和转移,临床样本中RACK1 O-GlcNAc糖基化升高与肿瘤发展和化疗后复发相关。

要点

  • 核糖体RACK1在Ser122位点被O-GlcNAc高度修饰,增强其稳定性、核糖体结合及与PKCβII相互作用。
  • RACK1 O-GlcNAc糖基化促进真核翻译起始因子4E磷酸化和癌基因翻译,驱动肝细胞癌发生。
  • 基因敲除RACK1 Ser122位点O-GlcNAc糖基化可抑制肿瘤发生、血管生成和转移。

核心结论

  • RACK1作为关键介质连接O-GlcNAc代谢与帽依赖性翻译,在肝细胞癌肿瘤发生中发挥作用。
  • 靶向RACK1 O-GlcNAc糖基化为肝细胞癌治疗提供有前景的选择。

研究设计与样本

  • 通过质谱分析确定RACK1 O-GlcNAc糖基化位点。
  • 使用肝细胞癌细胞系在体外检测RACK1 O-GlcNAc糖基化对癌基因因子翻译和肿瘤细胞行为的影响。
  • 使用转基因敲入小鼠在体内检测RACK1 O-GlcNAc糖基化在调节肝细胞癌肿瘤发生中的作用。
  • 在临床肝细胞癌样本中分析RACK1 O-GlcNAc糖基化与肿瘤进展和复发的相关性。

主要发现

  • 核糖体RACK1在Ser122位点被O-GlcNAc高度修饰。
  • RACK1的O-GlcNAc糖基化增强其蛋白稳定性、核糖体结合及与PKCβII(PRKCB)的相互作用,导致肝细胞癌细胞中真核翻译起始因子4E磷酸化增加和强效癌基因翻译。
  • 基因敲除RACK1 Ser122位点O-GlcNAc糖基化在体外和二乙基亚硝胺(DEN)诱导的肝细胞癌小鼠模型中显著抑制肿瘤发生、血管生成和转移。
  • 在肝细胞癌患者样本中观察到RACK1 O-GlcNAc糖基化增加,并与肿瘤发展和化疗后复发相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Aberrant oncogenic mRNA translation and protein O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) are general features during tumorigenesis. Nevertheless, whether and how these two pathways are interlinked remain unknown. Our previous study indicated that ribosomal receptor for activated C-kinase 1 (RACK1) promoted chemoresistance and growth in hepatocellular carcinoma (HCC). The aim of this study is to examine the role of RACK1 O-GlcNAcylation in oncogene translation and HCC carcinogenesis. METHODS: The site(s) of RACK1 for O-GlcNAcylation was mapped by mass spectrometry analysis. HCC cell lines were employed to examine the effects of RACK1 O-GlcNAcylation on the translation of oncogenic factors and behaviors of tumor cells in vitro. Transgenic knock-in mice were used to detect the role of RACK1 O-GlcNAcylation in modulating HCC tumorigenesis in vivo. The correlation of RACK1 O-GlcNAcylation with tumor progression and relapse were analyzed in clinical HCC samples. RESULTS: We found that ribosomal RACK1 was highly modified by O-GlcNAc at Ser122. O-GlcNAcylation of RACK1 enhanced its protein stability, ribosome binding and interaction with PKCβII (PRKCB), leading to increased eukaryotic translation initiation factor 4E phosphorylation and translation of potent oncogenes in HCC cells. Genetic ablation of RACK1 O-GlcNAcylation at Ser122 dramatically suppressed tumorigenesis, angiogenesis, and metastasis in vitro and in diethylnitrosamine (DEN)-induced HCC mouse model. Increased RACK1 O-GlcNAcylation was also observed in HCC patient samples and correlated with tumor development and recurrence after chemotherapy. CONCLUSIONS: These findings demonstrate that RACK1 acts as key mediator linking O-GlcNAc metabolism to cap-dependent translation during HCC tumorigenesis. Targeting RACK1 O-GlcNAcylation provides promising options for HCC treatment. LAY SUMMARY: O-GlcNAcylation of ribosomal receptor for activated C-kinase 1 at the amino acid serine122 promotes its stability, ribosome localization and interaction with the protein kinase, PKCβII, thus driving the translation of oncogenes and tumorigenesis of hepatocellular carcinoma. Increased O-GlcNAcylation of ribosomal receptor for activated C-kinase 1 is positively correlated with tumor growth, metastasis and recurrence in patients with hepatocellular carcinoma.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Duan F, Wu H, Jia D, et al. O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis. J Hepatol. 2018. PMID: 29454068. doi:10.1016/j.jhep.2018.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。